KKR & Co. Inc. — Director's Dealing 2014

Nov 6, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2014-11-06

Reporting Person: KKR Biosimilar L.P. (10% Owner)
Reporting Person: KKR Biosimilar GP LLC (10% Owner)
Reporting Person: KKR Fund Holdings L.P. (10% Owner)
Reporting Person: KKR Fund Holdings GP Ltd (10% Owner)
Reporting Person: KKR Group Holdings L.P. (10% Owner)
Reporting Person: KKR Group Ltd (10% Owner)
Reporting Person: KKR & Co. L.P. (10% Owner)
Reporting Person: KKR Management LLC (10% Owner)
Reporting Person: KRAVIS HENRY R (10% Owner)
Reporting Person: ROBERTS GEORGE R (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (2499499)		Indirect

Footnotes

F1: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.

F2: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and will automatically convert into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering.

F3: Not applicable.